RBC Capital maintains Zimmer Biomet Holdings at Outperform, raises price target to $125 from $110

RBC Capital kept Zimmer Biomet Holdings at Outperform, raising its price target to $125 from $110, citing a 13.5% upside from the Nov 4 close of $110.15. Recent analyst targets range from $100 to $125.

Original reporting
Published Nov 5, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RBC Capital maintains Zimmer Biomet Holdings at Outperform, raises price target to $125 from $110 — source image
Decision brief

The 30-second read

$ZBHBullishLow
01

Why it matters

The price target increase may prompt short-term buying, but without new fundamentals the effect could be short-lived.

02

Market read

Analyst target raise offers a modest trade idea; limited impact beyond sentiment.

03

What to watch

No new earnings or product news; the upgrade relies on analyst opinion alone.

Relevance 5/10Novelty 4/10Timing: today

Background

Zimmer Biomet is a leading orthopedic implant manufacturer; analyst coverage influences short-term sentiment.

Company-level read

Ticker impact

$ZBHBullishMedium confidence
Context

RBC Capital raised its price target on Zimmer Biomet Holdings to $125 from $110, indicating a bullish view.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise signals improved outlook but no new fundamental data; impact limited to sentiment-driven trades.

Market effects

May slightly lift the orthopedics/medical devices sector as a peer receives a positive rating.

U.S. market focus; limited regional effect.

Low global relevance.

Counterpoint

Target raise could be premature without fresh operational data; price may revert.

Key entities

  • RBC Capital

    Provided the upgraded price target.

  • Zimmer Biomet Holdings

    Subject of the analyst rating change.

Related articles

$ZBHMed

What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call

Zimmer Biomet (ZBH) reported Q3 sales growth of 13% in technology, bone cement, and surgical sales, but a 2.6% decline in global knee sales. CEO Tornos attributed knee underperformance to commercial execution. The company expects to launch its Monogram robotic system in early 2027. Q3 adjusted earnings were $1.90 per share, with margins declining but cash flow rising. Full-year sales growth guidance was raised to 4.4%-4.9%.

$ZBHMed

Truist raises Zimmer Biomet stock price target on robotics progress

Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.

$ZBHMed

Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips

Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.

$ZBHMedAI 8/10

Zimmer Biomet (ZBH) Q3 2026 Earnings Call Transcript

Zimmer Biomet (ZBH) reported Q3 2026 net sales of $2.63B, up 3.7% in constant currency. Growth was driven by hips, S.E.T., and technology, while knees declined 2.6%. The company raised its 2026 guidance, expecting 3% to 3.5% constant currency sales growth and $8.50 to $8.60 adjusted EPS. Strategic priorities include sales force transition, robotics expansion, and diversification.